TH 2101
Alternative Names: SN-38; SN-38-conjugate; TH-2101Latest Information Update: 09 May 2024
At a glance
- Originator Theratechnologies
- Class Antineoplastics; Camptothecins; Indolizines; Peptide drug conjugates; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Apr 2024 TH 2101 is available for licensing as of 13 Apr 2024. https://www.theratech.com/about/overview
- 10 Apr 2024 Preclinical trials in Cancer in Canada (unspecified route) prior to April 2024
- 09 Apr 2024 Interim adverse events and pharmacodynamic data from a preclinical studies in Cancer released by Theratechnologies